Fahimeh Safarnezhad-Tameshkel - Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
Nima Motamed - Associate Professor, Department of Social Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
Mohammad Hadi Karbalaie-Niya - Assistant Professor, Gastrointestinal and Liver Diseases Research Center AND Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Dhayaneethie Perumal - Assistant Professor, School of Science, Engineering and Computing, Kingston University, Kingston, United Kingdom
Nader Rezaie - Associate Professor, Department of Pulmonology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Shirin Izadi - Assistant Professor, Department of Pulmonology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Mitra Ranjbar - Professor, Department of Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
Mahdi Yadollahzadeh - Assistant Professor, Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
Behnam Behdad - Resident, Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
Gholamreza Hemmasi - Associate Professor, Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
Vahid Kaveh - Assistant Professor, Department of Hematology and Medical Oncology, School of Medicine, Iran University Medical Sciences, Tehran, Iran
Ali Arash Anoushirvani - Associate Professor, Department of Interventional Radiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Mojtaba Malek - Associate Professor, Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
Behzad Farahani - Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Ramin Eskandari - Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Mahshid Panahi - Assistant Professor, Department of Pathology, Iran University of Medical Sciences, Tehran, Iran
Mandana Rahimi - Assistant Professor, Department of Pathology, Iran University of Medical Sciences, Tehran, Iran
Sepideh Emami - Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Farhad Zamani - Professor, Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
Mohsen Farrokhpour - Assistant Professor, Department of Internal Medicine, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran

BACKGROUND: COVID-۱۹ was introduced by the World Health Organization (WHO) as a global pandemic. The spectrum of symptoms of the disease ranges from a mild cold to death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease.METHODS: The study sample included ۴۳۸ patients hospitalized with COVID-۱۹; however, the troponin data of ۶ patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-۱۹. Troponin levels were checked in all patients on day ۱ and day ۳ of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-۱۹.RESULTS: The mean age of patients was ۶۱.۲۹ ± ۱۵.۸۴ years. Among the ۴۳۲ patients tested on day ۱ of hospitalization, ۲۴ patients (۵.۶%) tested positive (Troponin ۱), and among the ۳۰۳ patients tested on day ۳, ۱۳ patients (۴.۳%) tested positive (Troponin ۲). Based on our results, Troponin ۱ showed an independent association with both death (۳.۰۰۸ [۹۵%CI = ۱.۰۹۱-۸.۲۹۰]; P = ۰.۰۳۳) and need for ICU admission (۸.۴۹۹ [۹۵%CI = ۳.۳۱۶-۲۱.۷۸۸]; P < ۰.۰۰۱) in multiple logistic regression analysis. Moreover, the status of Troponin ۲ had an independent significant association with both death (۴.۱۵۹ [۹۵%CI = ۱.۱۵۶-۱۴.۹۶۱]; P = ۰.۰۲۹) and ICU admission (۷.۷۹۶ [۹۵%CI = ۱.۹۵۴-۳۱.۰۹۷]; P = ۰.۰۰۴).CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-۱۹. The serial assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians.

Troponin, COVID-۱۹, Mortality